The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.
Some of the key takeaways from the Obesity Pipeline Report:
Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years.
Obesity companies working in the treatment market are Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Novo Nordisk, Sciwind Biosciences, Empros Pharma, and others, are developing therapies for the Obesity treatment
Emerging Obesity therapies such as – CT-868, Tirzepatide, Semaglutide, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, NNC0480-0389, XW003, EMP-16, and others are expected to have a significant impact on the Obesity market in the coming years.
In October 2022, The US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the examination of tirzepatide for the treatment of individuals with obesity or overweight with weight-related comorbidities, according to an announcement from Eli Lilly & Company
In February 2022, To assess the effectiveness, safety, and tolerability of CT-868 given for 26 weeks to overweight and obese participants with Type 2 diabetes mellitus, Carmot Therapeutics started a randomised, double-blind, placebo-controlled, parallel-group, multi-center trial
In July 2021, In order to promote research, develop, and commercialise small molecule drugs that are aimed against the GPR75 target and have the potential to treat obesity and associated co-morbidities, AstraZeneca partnered with Regeneron
In June 2021, IBI362, a dual agonist for the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR), has successfully dosed its first subject in a Phase II clinical trial (NCT04904913) in China, according to an announcement from Innovent Biologics
In April 2021, Two Phase II studies of the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH) and obesity were recently disclosed by Boehringer Ingelheim and Zealand Pharma
Obesity is understood to be a chronic or non-communicable condition that affects, along with overweight, and is largely related with excess adiposity or body fatness, which can express physiologically and not just with regard to physical size.
Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
CT-868: Carmot Therapeutics
Tirzepatide: Eli Lilly and Company
RZL-012: Raziel Therapeutics
EMP16: Empros Pharma
ZP 8396: Zealand Pharma
ERX-1000: ERX Pharmaceuticals
Semaglutide: Oral Novo Nordisk
TNX-2900: Tonix Pharmaceuticals
Thermostem: BioRestorative Therapies
SCO-267: SCOHIA PHARMA
CT-181: Click Therapeutics
HM15136: Hanmi Pharmaceuticals
DD03 D&D: Pharmatech
CBW-520: Caliway Biopharmaceutics
NPM 139: Nano Precision Medical
BK-1701: Bukwang Pharmaceutical
NNC0480-0389: Novo Nordisk
XW003: Sciwind Biosciences
EMP-16: Empros Pharma
Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Obesity Pipeline Therapeutics Assessment
Obesity Assessment by Product Type
Obesity By Stage and Product Type
Obesity Assessment by Route of Administration
Obesity By Stage and Route of Administration
Obesity Assessment by Molecule Type
Obesity by Stage and Molecule Type
DelveInsight’s Obesity Report covers around 130+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies
Some of the key companies in the Obesity Therapeutics Market include:
Key companies developing therapies for Obesity are – Novo Nordisk A/S, Eli Lilly and Company, Novartis International AG, Johnson & Johnson, AstraZeneca PLC, Roche Holding AG, Pfizer Inc., Merck & Co., Inc., Sanofi, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Bristol Myers Squibb, Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., Vivus Inc., Zafgen Inc., NantKwest Inc., Rhythm Pharmaceuticals, Inc., EnteroMedics Inc., Gelesis, Inc., Allergan PLC, Medifast, Inc., Obalon Therapeutics, Inc., Herbalife Nutrition Ltd., GNC Holdings, Inc., Nutrisystem, Inc., WW International, Inc. (formerly Weight Watchers), Slimming World, and others.
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Obesity drugs and therapies
Obesity Pipeline Market Drivers
Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.
Obesity Pipeline Market Barriers
However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.
Scope of Obesity Pipeline Drug Insight
Key Obesity Companies: Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Novo Nordisk, Sciwind Biosciences, Empros Pharma, and others
Key Obesity Therapies: CT-868, Tirzepatide, Semaglutide, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, NNC0480-0389, XW003, EMP-16, and others
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials
Table of Contents
Obesity Report Introduction
Obesity Executive Summary
Obesity- Analytical Perspective In-depth Commercial Assessment
Obesity Pipeline Therapeutics
Obesity Late Stage Products (Phase II/III)
Obesity Mid Stage Products (Phase II)
Obesity Early Stage Products (Phase I)
Obesity Preclinical Stage Products
Obesity Therapeutics Assessment
Obesity Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers and Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States